Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00592670 · ClinicalTrials.gov registry record · NA

Hypoglycemia Associated Autonomic Failure in Type 1 DM

A NA study of Type 1 Diabetes, sponsored by Vanderbilt University.

Completed
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT00592670 is a NA study of Type 1 Diabetes that has completed, run by Vanderbilt University. The registered enrollment target is 48 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00592670, a NA study of Type 1 Diabetes, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et al., 1996). Because of the increased prevalence of depression in those with diabetes, it is critical to discover what affect the antidepressant therapy may have on counterregulatory responses to hypoglycemia. This study hypothesizes that chronic administration of SSRIs may result in a blunted counterregulatory response to hypoglycemia, thereby leaving individuals more susceptible to hypoglycemia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Fluoxetine

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2005-03
Est. Completion 2008-10
Phase NA

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT00592670

The ClinicalTrials.gov registry entry for NCT00592670 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (94% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00592670 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00592670 about?

NCT00592670 is a clinical study titled "Hypoglycemia Associated Autonomic Failure in Type 1 DM". It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et al., 1996). Because of the incr...

What is the current status of trial NCT00592670?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2005-03. Estimated completion is 2008-10.

What conditions does trial NCT00592670 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT00592670?

The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).

Who is sponsoring clinical trial NCT00592670?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00592670 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.